Showing 9851-9860 of 20328 results for "".
- Immune-Targeting Therapy with Aldesleukin: A New Frontier in Post-MI Carehttps://reachmd.com/news/immune-targeting-therapy-with-aldesleukin-a-new-frontier-in-post-mi-care/2485273/IVORY trials show low-dose aldesleukin after acute myocardial infarction reduced vascular inflammation by an average of nearly 8% on imaging and blood markers — a targeted signal in a defined post‑MI subgroup.
- Inflammation and Clinical Impact in Long COVID: Emerging Insightshttps://reachmd.com/news/inflammation-and-clinical-impact-in-long-covid-emerging-insights/2485269/Emerging evidence links persistent inflammation and circulating micro‑clots to multisystem Long COVID morbidity, offering a plausible biological pa
- Immunonutrition in Ulcerative Colitis: A Preclinical Study of Arginine, Glutamine, and HMBhttps://reachmd.com/news/immunonutrition-in-ulcerative-colitis-a-preclinical-study-of-arginine-glutamine-and-hmb/2485271/In a single DSS-induced rat study, oral supplementation with arginine, glutamine, and HMB produced greater histopathological improvement and broader redu
- Microbiome and Dietary Interventions in Infection Managementhttps://reachmd.com/news/microbiome-and-dietary-interventions-in-infection-management/2485278/High-protein diets markedly reduced Vibrio cholerae intestinal colonization in a recent preclinical model
- Enhancing Pediatric Emergency Triage and Analgesic Management: New Insights and Evolving Practiceshttps://reachmd.com/news/enhancing-pediatric-emergency-triage-and-analgesic-management-new-insights-and-evolving-practices/2485277/ICASS demonstrates superior sensitivity for identifying children likely to require pediatric trauma-center resources, supporting a practice-ready shift in how undertriage
- Analysis: Ustekinumab, IL-23 Inhibitors Show Higher Drug Survival in Psoriasishttps://reachmd.com/news/analysis-ustekinumab-il-23-inhibitors-show-higher-drug-survival-in-psoriasis/2485295/A new Danish cohort study using data from the DERMBIO registry suggests ustekinumab was linked with the best 5-year survival of comparators in bionaive patients with psoriasis. The analysis included a total of 7,193 treatment
- Surgeon Introduces “Preservation Lasers” Protocol for No-Downtime, Collagen-Supportive Skin Renewalhttps://reachmd.com/news/surgeon-introduces-preservation-lasers-protocol-for-no-downtime-collagen-supportive-skin-renewal/2485260/As patients increasingly seek preventative, low-downtime skin treatments, combination laser protocols are emerging as a new standard in aesthetic care. Double board-certified facial plastic surgeon Anil Shah, MD, FACS, is responding to this shift with the launch of
- TOGETHER-PsA: Weight Loss Plus PsA Control with Ixekizumab and Tirzepatidehttps://reachmd.com/news/together-psa-weight-loss-plus-psa-control-with-ixekizumab-and-tirzepatide/2485259/In the phase 3b TOGETHER-PsA trial, ixekizumab (Taltz, Eli Lilly) used in combination with tirzepatide (Zepbound, Eli Lilly) was more effective than ixekizumab monotherapy in adults with active psoriatic arthritis (PsA) who also have obesity or are overweight with a
- Evaluating Isoniazid Hepatotoxicity in Rheumatic Disease: Risks and Alternativeshttps://reachmd.com/news/evaluating-isoniazid-hepatotoxicity-in-rheumatic-disease-risks-and-alternatives/2485251/In patients with autoimmune rheumatic disease and prior DMARD‑related liver injury, isoniazid for latent tuberculosis infection (LTBI) was associated with a 27.6% incidence of hepatotoxicity in t
- Community-Based Asthma Interventions: Lessons from the Navajo Nationhttps://reachmd.com/news/community-based-asthma-interventions-lessons-from-the-navajo-nation/2485253/A recent study found that a community asthma program on the Navajo Nation increased pediatric asthma care‑seeking and awareness during the COVID‑19 pandemic. Program mo